Table 3.

Summary of the linear models explaining the MDS-UPDRS components at baseline (BL) and the MDS-UPDRS variation (ΔMDS-UPDRS) 1 year after the baseline.

Time point	Dependent variable	Model predictors: p-value										R2	Adj R2	F-, p-value
		GM vol in PFC and PMC	MD in OP	MD in PN	FA in PT	DAT in Put	Interaction DAT in Put – MD PN	Interaction DAT in Put – GM vol in PFC and PMC and IN	Age	Gender	Dominant side
BL	MDS-UPDRS1	0.37	0.11	0.75	0.81	0.35	0.05	0.01	0.37	0.9	0.83	0.12	0.09	0.82, 0.57
	MDS-UPDRS2	0.30	0.01∗	0.08	0.17	−2 × 10−4∗	0.39	0.10	0.01∗	0.87	0.12	0.38	0.29	4, 2 × 10−4∗
	MDS-UPDRS3	0.88	0.09	0.40	0.85	0.50	0.06	0.11	0.02	0.13	0.22	0.21	0.09	2, 0.08
	MDS-UPDRS tot	0.9	0.002∗	0.23	0.50	0.006∗	0.03	0.002∗	0.01	0.31	0.70	0.31	0.21	4.85, 0.003∗
Δ	MDS-UPDRS1 PD on med+no med	0.78	0.29	0.25	0.44	0.37	0.74	0.58	0.13	0.35	0.34	0.15	0.03	1.02, 0.43
	MDS-UPDRS1 PD on med	0.87	0.70	0.003∗	0.47	0.01∗	0.002∗	0.32	0.008∗	0.96	0.87	0.47	0.27	5.7, 0.004∗
	MDS-UPDRS1 PD no med	0.28	0.11	0.44	0.38	0.5	0.9	0.21	0.44	0.09	0.06	0.19	0.01	1, 0.41
	MDS-UPDRS2 PD on med+no med	0.02	0.30	0.36	0.03	0.03	0.03	0.80	0.01	0.12	0.18	0.22	0.09	1.71, 0.09
	MDS-UPDRS2 PD on med	0.006∗	0.009∗	0.17	0.01∗	0.004∗	0.25	0.004∗	0.66	0.05	0.27	0.37	0.15	4.68, 0.01∗
	MDS-UPDRS2 PD no med	0.003∗	0.02	0.09	0.01∗	0.01∗	0.23	0.01∗	0.55	0.6	0.11	0.37	0.21	4.75, 0.01∗
	MDS-UPDRS3 PD on med+no med	0.02	0.96	0.94	0.01	0.03	0.41	0.20	0.41	0.22	0.25	0.15	0.05	1.1, 0.38
	MDS-UPDRS3 PD on med	0.76	0.74	0.47	0.34	0.95	0.74	0.48	0.77	0.99	0.44	0.27	0.13	0.59, 0.83
	MDS-UPDRS3 PD no med	0.61	0.19	0.9	0.5	0.6	0.02	0.09	0.87	0.28	0.7	0.20	0.03	1.14, 0.35
	MDS-UPDRS tot PD on med+no med	0.02	0.98	0.92	0.01	0.01	0.03	0.71	0.08	0.98	0.38	0.17	0.03	1.3, 0.31
	MDS-UPDRS tot PD on med	0.82	0.58	0.69	0.58	0.5	0.06	0.61	0.79	0.58	0.38	0.21	0.05	0.89, 0.54
	MDS-UPDRS tot PD no med	0.14	0.24	0.03	0.34	0.04	0.73	0.37	0.86	0.16	0.22	0.27	0.11	1.69, 0.11

Models for the ΔMDS-UPDRS were estimated separately for the patients without medication 1 year after baseline (no med), for the patients on L-Dopa 1 year after baseline (on med) and for the patients of both groups together (on med + no med). The model predictors were the mean imaging values extracted from the following regions: IN, insula; OP, operculum; PFC, prefrontal cortex; PMC, premotor cortex; PN, pons nuclei; Put, putamen; PT, pontine tegmentum. We report the p-value for every regressor, and the determination coefficient (R²), adjusted R², f-value, and p-value for every model. Bold characters and “^∗” indicate a significant (p < 0.05) model – (p < 0.01) regressors.